- Prev Close
- 0.0045
- Today's Open
- 0.0008
- Day's Range
- 0.0008-0.0009
- Volume
- 2,021,833
- Dollar Volume
- $766.5
- Avg Vol(5-day)
- 2,135,964
- Avg Vol(1-month)
- 2,888,296

http://www.eastonpharmaceuticalsinc.com
Description
Easton Pharmaceuticals, Inc. is a development-stage company engaged in various pharmaceutical sectors and others industries. The Company has a transdermal delivery technology (Viorra Delivery Matrix or VDM), which is incorporated in a line of therapeutic over-the-counter (OTC) products. The Company owns topically-delivered drugs and therapeutic/cosmetic healthcare products focused on cancer and other health problems geared towards female sexual dysfunction, wound healing, pain, motion sickness and other conditions. The Company's products are in various stages of commercialization. The Company's products include Nauseasol, which is a motion sickness gel; Skin Renou HA, which is an anti-aging wrinkle cream; Kenestrin Gel, which is a is a pain relief gel; Viorra, which serves as an aid to the relief of female sexual arousal disorder (FSAD); XILIVE, which is an early-stage cancer drug, and FSAD) drug, which includes a water-based complex polymer matrix.
Company Address
425 University AvenueToronto, ON M5G1T6
United States
Have a suggestion?
Please Contact Us to let us know.
-
Easton Pharmaceuticals Turns to Profit in Q1, Provides Business Update
June 13, 2019
-
Easton Closes Purchase of Food Processing Company Specializing in Baked Goods with Projected Revenues Over $20,000,000 per Year and Positioned to Enter the Cannabis Edibles Market
April 24, 2019
-
Easton Provides Update on the Closing of its Agreement To Acquire Commercial Bakery
April 12, 2019
-
Easton Provides Update on the Closing of its Agreement To Acquire Commercial Bakery with Projected Revenues Over $20,000,000 per Year and Positioned to Enter the Cannabis Edibles Market
April 8, 2019
-
Easton Announces Signing of Joint Venture Agreement for the Purchase and Development of 9 Townhomes with Revenue in Excess of $4 Million and Provides Update on its Framing Contract with Revenues of $770K for Q1
April 2, 2019
-
Easton Signs LOI with Licensed Producer of Cannabis to Expand its Operations and Participate in its Cannabis Edibles Division
March 27, 2019
-
Easton Announces Filing of Its Financial Statements for the Year Ended December 31, 2018 with a Revenue Increase of 145% Over 2017 and Provides General Business Update
March 18, 2019
-
Easton Announces Status Update On Its $2,600,000 Framing Contract To Construct 150 Homes, Including Update on Its Development Project in Cobourg, Ontario
March 13, 2019
-
Easton Commences Cannabis Edibles Division and Announces Updates on Its Filing for the Period Ended December 31, 2018
March 11, 2019
-
Easton Signs Agreement to Acquire Commercial Bakery with Projected Revenues Over $20,000,000 per Year and Positioned to Enter the Cannabis Edibles Market
March 5, 2019
-
Easton Announces Updates on Its $2,600,000 Framing Contract to Construct 150 Homes as Well as Other Initiatives
February 5, 2019
-
Easton Pharmaceuticals Provides Company Update Including Hotel Acquisition in Toronto, BAYER Agreement and Casino Resort in Greece
December 12, 2018
-
Easton Pharmaceuticals Is Short-Listed to Acquire an Interest in an Operating Casino and Hotel Resort in Loutraki, Greece with Revenues in Excess of 60 Million Euro Per Year
October 1, 2018
-
Easton Pharmaceuticals Reaches Agreement to Take Over Hotel and $17,000,000 Real Estate Asset in Heart of Toronto, Canada
September 27, 2018
-
Easton Pharmaceuticals Announces It Has Entered Into High Level Negotiations To Take Over a Profitable Hotel and a $17,000,000 Real Estate Asset Located In The Heart of Toronto, Ontario, Canada
September 11, 2018
-
Easton Pharmaceuticals Strengthens its Board of Directors While Enhancing Existing Businesses and Moves Towards New Sectors and Industries
June 25, 2018
-
Easton Pharmaceuticals Announces New Director / Officer to Its Board and Updates to Business Direction
June 20, 2018
-
Easton Pharmaceuticals Announces That Easton and Its JV Partner, Alliance Group, Have Generated $40,000 in Revenues in the First Week of Operations
June 11, 2018
-
Easton Pharmaceuticals Announces That Revenue Generating Operations Have Commenced From Its Alliance Property and Businesses
June 4, 2018
-
Easton Pharmaceuticals Announces it is Moving Towards a Letter of Intent With an AMPR Applicant Towards a Marijuana Cultivators / Growers License for Canada; Provides Other Updates
April 17, 2018
-
Easton Pharmaceuticals Announces BAYER Agreement Update
April 16, 2018
-
Easton Pharmaceuticals Announces Development of a Blockchain and Cryptocurrency Initiative
March 21, 2018
-
Easton Pharmaceuticals Announces It Has Commenced Negotiations With An AMPR Applicant Towards a Marijuana Cultivators / Growers License For Canada; Provides iBliss Update
March 14, 2018
-
Easton Pharmaceuticals Announces Key Management Addition With the Appointment of Dr. Daniel Bagi, M.D. to the Board of Directors; Provides Other Updates
February 20, 2018
-
Easton Pharmaceuticals Announces Negotiations for a New Sub-Distribution Agreement for One of Its Woman’s Diagnostic / Treatment Products & Provides Update on Its Alliance Operations
February 6, 2018
-
Easton Pharmaceuticals Announces The Signing Of Closed Sub-Distribution Agreement for Product VS-Sense
January 25, 2018
-
Data Projects Increased Demand for the Legalized Cannabis Market
January 9, 2018
-
Easton Pharmaceuticals & Partner BMV Medica Announce Delivery and Launch of AmnioSense (AL-Sense) in Mexico; Delivery Date for Purchase Order From Windsor Pharmaceuticals for Central America
December 6, 2017
-
Profits From Legal Cannabis Sales Projected to Rise
November 29, 2017
-
Easton Pharmaceuticals Announces Final Payment Completing $1.3 Million JV Agreement With Alliance Group For a 50% Property Ownership Interest and Various Businesses Including The Cultivation of Medical / Recreational Marijuana For National Canadian Market
October 20, 2017
-
Market Research Projects Legal Cannabis Industry to Benefit From New Businesses
October 11, 2017
-
Easton Pharmaceuticals & JV Partner Alliance Group Announces It Has Cleared Final Hurdles Toward Allowing For The Cultivation of Medical / Recreational Marijuana For National Canadian Market
October 10, 2017
-
Innovative Payment Solutions Blossom in the Expanding Cannabis Industry
October 5, 2017
-
Data Indicates That the Cannabis Market is Projected to Grow
September 28, 2017
-
Global Legal Cannabis Sales Projected to Grow
September 19, 2017
-
Legal Cannabis and CBD Products are Projected to Grow
September 13, 2017
-
Easton Pharmaceuticals Announces That Its Partner Windsor Pharmaceuticals Has Received Regulatory Approvals For Products VS-Sense and AL-Sense For Central America and The Caribbean
September 12, 2017
-
Easton Pharmaceuticals Announces $1,000,000 cdn In Payments Toward Alliance Group JV / Partnership Agreement; Announces $8,000,000 cdn Aggregate LOI Contract
September 5, 2017
-
Developments in the Erectile Dysfunction Markets
August 28, 2017
-
Easton Pharmaceuticals and Alliance Group Announces the Closing Of Its First Aggregate Contract Valued At $6,000,000 CDN On Its 90 Acre Portion Of Industrial Zoned Land
August 23, 2017
-
Revenues in Legal Cannabis Continue to Skyrocket as Demand for CBD Based Products Rapidly Explode in Popularity
August 17, 2017
-
Easton Pharmaceuticals Announces Finalized Sub-Distribution Agreement With Gedeon Richter S.A.P.I de C.V. For Product Launch Of AmnioSense (AL-Sense)
August 10, 2017
-
Recreational Cannabis Sales to Grow Faster Than Medical Cannabis Sales
July 31, 2017
-
Easton Pharmaceuticals Announces It Has Received $400,000 USD In Product Purchase Orders For The Current Quarter From Its Woman’s Diagnostic And Treatment Products Business For The Mexico Market
June 26, 2017
-
Easton Pharmaceuticals Announces It Has Signed an LOI to Acquire An Interest in a 45 Acre Parcel for the Cultivation of Medical Marijuana in Toronto, Canada; Wholly Owned Subsidiary, iBliss in Birmingham’s UK Vaper Expo
May 24, 2017
-
Easton Pharmaceuticals Announces Signing NDA and Starts Negotiations For Acquisition
April 24, 2017
-
Easton Pharmaceuticals Announces Signing Of Purchase Agreement Completing The Acquisition Of Revenue Producing Vaporizer and e-Liquids Manufacturer iBliss, Inc.
April 20, 2017
-
Easton Pharmaceuticals Announces Advancing $300,000 Payment To CommonSense Ltd. Paving The Way For The Anticipated Closing Of Exclusive Sub-Distribution Agreement For Product AL-Sense with 2nd Quarter Launch
March 22, 2017
-
Easton Pharmaceuticals Provides Update On Acquiring Major Vaporizer and e-Liquids Manufacturer iBliss, Inc.
March 8, 2017
-
Easton Pharmaceuticals / BMV Medica Announces Successful Product Sales Launch Conference Of Product Gynofit and Additional Distribution of Product AL-Sense (AmnioSense) With Multi-National Pharmaceutical Company Gedeon Richter
February 21, 2017
-
Easton Pharmaceuticals and BMV Medica Announces First Shipment of Gynofit To Multi-National Pharmaceutical Company, Gedeon Richter, Towards Its Purchase Order, Has Been Received For February 16th Product Launch in Puerto Vallarta, Mexico
February 3, 2017
-
SmallCap Companies Trending in Various Sectors
December 28, 2016
-
FinancialBuzz.com: Small Companies With Recent News
December 14, 2016